Category: Peptide Q&A
-
Can tesamorelin reduce fibrosis in visceral adipose tissue, and what is the evidence for this in animal models or human biopsies?
Can tesamorelin reduce fibrosis in visceral adipose tissue, and what is the evidence for this in animal models or human biopsies?
-
Tesamorelin: Research Evidence & Trials
Tesamorelin — Research Evidence & Trials: evidence-based guide.
-
What is the risk of developing insulin resistance or hyperglycemia during tesamorelin therapy, and how can it be mitigated?
What is the risk of developing insulin resistance or hyperglycemia during tesamorelin therapy, and how can it be mitigated?
-
Does tesamorelin improve muscle mass or strength in patients with sarcopenia or HIV-related wasting?
Does tesamorelin improve muscle mass or strength in patients with sarcopenia or HIV-related wasting?
-
What is the long-term safety and efficacy data on tesamorelin beyond 12 months of treatment in clinical trials?
What is the long-term safety and efficacy data on tesamorelin beyond 12 months of treatment in clinical trials?
-
Is there any preclinical evidence suggesting tesamorelin may enhance neurogenesis or synaptic plasticity in the hippocampus?
Is there any preclinical evidence suggesting tesamorelin may enhance neurogenesis or synaptic plasticity in the hippocampus?
-
Tesamorelin: Practical & Buying Guidance
Tesamorelin — Practical & Buying Guidance: evidence-based guide.
-
How does tesamorelin compare to lifestyle interventions or GLP-1 receptor agonists in reducing visceral adiposity?
How does tesamorelin compare to lifestyle interventions or GLP-1 receptor agonists in reducing visceral adiposity?
-
How does tesamorelin affect brown adipose tissue activity and thermogenesis in humans?
How does tesamorelin affect brown adipose tissue activity and thermogenesis in humans?